100334-95-0Relevant academic research and scientific papers
Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them
Liu, Jie,Zhang, Jianrun,Wang, Huailing,Liu, Zhijun,Zhang, Cao,Jiang, Zhenlei,Chen, Heru
, p. 50 - 61 (2017)
34 Xanthones were synthesized by microwave assisted technique. Their in?vitro inhibition activities against five cell lines growth were evaluated. The SAR has been thoroughly discussed. 7-Bromo-1,3-dihydroxy-9H-xanthen-9-one (3-1) was confirmed as the most active agent against MDA-MB-231?cell line growth with an IC50 of 0.46?±?0.03?μM. Combination of 3-1 and 5,6-dimethylxanthone-4-acetic acid (DMXAA) showed the best synergistic effect. Apoptosis analysis indicated different contributions of early/late apoptosis and necrosis to cell death for both monomers and the combination. Western Blot implied that the combination regulated p53/MDM2 to a better healthy state. Furthermore, 3-1 and DMXAA arrested more cells on G2/M phase; while the combination arrested more cells on S phase. All the evidences support that the 3-1/DMXAA combination is a better anti-cancer therapy.
Synthesis and antitumor, antityrosinase, and antioxidant activities of xanthone
Zhou, Bei-Dou,Zeng, Li-Lan,Tong, Yu-Gui,Fang, Jia-Ying,Ruan, Zhi-Peng,Zeng, Xiao-Yun,Fang, Yuan-Yuan,Xu, Gui-Fen,Hu, Dong-Bao
, p. 467 - 476 (2018)
Ten substituted 1,3-dihydroxyxanthones were synthesized in one step. The yields ranged from 40 to 76%. Compounds 8–10 were first reported. Next, the compounds’ in vitro anti-proliferative activities against nine human cancer cell lines, antityrosinase, and antioxidant activities were evaluated. Compounds 1, 4, 6–7, and 9–10 exhibited enhanced cytotoxicity against certain cancer cells. Compounds 2, 8, 9, and 10 inhibited tyrosinase activity to a certain extent. In addition, compound 4 exhibited the best antioxidant activity, which was consistent with theoretical calculations. These results demonstrated that compounds 1–2, 4, and 6–10 were promising leads for further investigation.
Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity
Liu, Jie,Zhang, Cao,Wang, Huailing,Zhang, Lei,Jiang, Zhenlei,Zhang, Jianrun,Liu, Zhijun,Chen, Heru
, p. 158 - 172 (2018)
Fifty 1,3-dioxyxanthone nitrates (4a ～ i-n, n = 1–6) were designed and synthesized based on molecular similarity strategy. Incorporation of nitrate into 1,3-dioxyxanthones with electron-donating groups at 6–8 position brought about synergistic anticancer effect. Among them, compound 4g-4 was confirmed the most active agent against HepG-2 cells growth with an IC50 of 0.33 ± 0.06 μM. It dose-dependently increased intramolecular NO levels. This activity was attenuated by either NO scavenger PTIO or mitochondrial aldehyde dehydrogenase (mtADH) inhibitor PCDA. Apoptosis analysis indicated different contributions of early/late apoptosis and necrosis to cell death for different dose of 4g-4. 4g-4 arrested more cells on S phase. Results from Western Blot implied that 4g-4 regulated p53/MDM2 to promote cancer cell apoptosis. All the evidences support that 4g-4 is a promising anti-cancer agent.
The design and synthesis of n-xanthone benzenesulfonamides as novel phosphoglycerate mutase 1 (PGAM1) inhibitors
Wang, Penghui,Jiang, Lulu,Cao, Yang,Ye, Deyong,Zhou, Lu
, (2018)
Upregulation of phosphoglycerate mutase 1 (PGAM1) has been identified as one common phenomenon in a variety of cancers. Inhibition of PGAM1 provides a new promising therapeutic strategy for cancer treatment. Herein, based on our previous work, a series of new N-xanthone benzenesulfonamides were discovered as novel PGAM1 inhibitors. The representative molecule 15h, with an IC50 of 2.1 μM, showed an enhanced PGAM1 inhibitory activity and higher enzyme inhibitory specificity compared to PGMI-004A, as well as a slightly improved antiproliferative activity.
Donor compound as Xanthone-NO well as preparation method and application thereof in preparation of anti-tumor drugs (by machine translation)
-
Page/Page column 5; 6; 12-14, (2020/01/04)
The invention belongs to the technical field of, antitumor drugs, and Xanthone - NO discloses a compound of formula I as well as a preparation method thereof, and an Xanthone - NO. application according to the: invention in preparation of an antitumor drug. In-flight vehicle, R1 , R2 , R3 The compound of the present invention is H, OH, Cl, Br prepared F;n＝2-8. from substituted salicylic acid and m-taminophen and then is prepared xanthones, from the 1,n - substituted salicylic acid and the 3 - O - M xanthone,bromophenol to. prepare the compound of the, present invention for inhibiting the tumor cell proliferation in vitro and, inhibiting the apoptosis of tumor cells by multiple, targets. (by machine translation)
